Immunome (IMNM) Return on Capital Employed (2020 - 2026)
Immunome (IMNM) posted Return on Capital Employed of 38.27% for Q1 2026, up 23.8% on a QoQ basis from 50.22% in Q4 2025, and up 4542.0% year-over-year from 0.82% in Q1 2025.
Immunome (IMNM) Return on Capital Employed (2020 - 2026) Analysis & Trends
Immunome's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 38.27% for Q1 2026.
- Quarterly Return on Capital Employed rose 4542.0% year-over-year to 38.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.27% (up 4542.0% YoY) and the FY2025 annual result came in at 53.78%, up 16452.0% from the prior year.
- Return on Capital Employed was 38.27% for Q1 2026 at Immunome, up from 50.22% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 38.27% in Q1 2026 and bottomed at 264.18% in Q1 2023.
- A 5-year average of 112.7% and a median of 104.0% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 18774 bps — and 2024, when it soared 14748 bps.
- Immunome's Return on Capital Employed stood at 184.83% in 2022, then soared by 40 bps to 110.61% in 2023, then sank by 42 bps to 157.42% in 2024, then surged by 68 bps to 50.22% in 2025, then rose by 24 bps to 38.27% in 2026.
- Business Quant data shows IMNM's Return on Capital Employed at 38.27% in Q1 2026, 50.22% in Q4 2025, and 87.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | -38.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.27% |
| Dec 31, 2025 | -50.22% |
| Sep 30, 2025 | -87.92% |
| Jun 30, 2025 | -75.72% |
| Mar 31, 2025 | -83.68% |
| Dec 31, 2024 | -157.42% |
| Sep 30, 2024 | -133.94% |
| Jun 30, 2024 | -101.31% |
| Mar 31, 2024 | -116.71% |
| Dec 31, 2023 | -110.61% |
| Sep 30, 2023 | -51.29% |
| Jun 30, 2023 | -144.51% |
| Mar 31, 2023 | -264.18% |
| Dec 31, 2022 | -184.83% |
| Sep 30, 2022 | -134.82% |
| Jun 30, 2022 | -104.00% |
| Mar 31, 2022 | -76.44% |
| Dec 31, 2021 | -49.90% |
| Sep 30, 2021 | -38.56% |
| Jun 30, 2021 | -33.16% |